← 返回

黑色素瘤治疗的进展:从手术到免疫治疗

英文原题:Advancements in Melanoma Therapies: From Surgery to Immunotherapy.

查看英文原题

Advancements in Melanoma Therapies: From Surgery to Immunotherapy.

PubMed 2024/07/27(内容时间) Curr Treat Options Oncol Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

黑色素瘤是侵袭性最强、致死率最高的皮肤癌。治疗方案取决于疾病分期、肿瘤部位及其从原发部位扩散的范围。黑色素瘤治疗已取得重大进展,尤其在靶向治疗和免疫治疗方面。早期黑色素瘤主要采用手术切除,通常疗效良好。疾病发生转移后,免疫治疗和靶向治疗等系统治疗变得日益重要。对黑色素瘤驱动突变的发现影响了治疗策略;针对这些突变的靶向疗法与传统化疗相比,可提高缓解率并减少毒性。此外,免疫检查点抑制剂和TIL(肿瘤浸润淋巴细胞)疗法等免疫治疗的发展,在有效对抗癌细胞方面显示出令人鼓舞的结果。这些治疗药物疗效更好、副作用更易耐受,改善了患者接受治疗期间的生活质量。未来黑色素瘤治疗可能采用多模式方案,根据患者个体特征组合手术、靶向治疗和免疫治疗,从而改善生存率和健康结局。

展开英文摘要原文

Melanoma is defined as the most aggressive and deadly form of skin cancer. The treatment of melanoma depends on the disease stage, tumor location, and extent of its spread from its point of origin. Melanoma treatment has made significant advances, notably in the context of targeted and immunotherapies. Surgical resection is the main therapeutic option for earlystage melanoma, and it provides favourable outcomes.

With disease metastasis, systemic treatments such as immunotherapy and targeted therapy become increasingly important. The identification of mutations that lead to melanoma has influenced treatment strategies. Targeted therapies focusing on these mutations offer improved response rates and fewer toxicities than conventional chemotherapy.

Furthermore, developing immunotherapies, including checkpoint inhibitors and tumor-infiltrating lymphocyte (TIL) therapies, has demonstrated encouraging outcomes in effectively combating cancer cells. These therapeutic agents demonstrate superior effectiveness and a more tolerable side-effect profile, improving the quality of life for patients receiving treatment.

The future of melanoma treatment may involve a multimodal approach consisting of a combination of surgery, targeted therapy, and immunotherapy adapted to each patient's profile. This approach may improve survival rates and health outcomes.

论文信息

作者
Shajari N、Baradaran B、Tohidkia MR、Nasiri H、Sepehri M、Setayesh S、Aghebati-Maleki L
第一作者单位
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.Iran
通讯作者单位
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. leili_aghebati_maleki@yahoo.com.Iran
文献类型
综述
期刊
Current treatment options in oncology2024 Aug
原文标识
PubMed 39066854 · DOI 10.1007/s11864-024-01239-8